Evidence map›Paper›PMID 38646400›Full record

ReviewCureus2024

A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022).

Shannon Giliberto, Rhea Shishodia, Meredith Nastruz, Chamandeep Brar, Sadeepa Bulathsinhala, Jonathan Terry, Sudhakar Pemminati, Sudhakar K Shenoy

Erratum issuedOpen access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Shannon GilibertoDepartment of Biomedical Education, California Health Sciences University College of Osteopathic Medicine, Clovis, USA.
Rhea ShishodiaDepartment of Biomedical Education, California Health Sciences University College of Osteopathic Medicine, Clovis, USA.
Meredith NastruzDepartment of Biomedical Education, California Health Sciences University College of Osteopathic Medicine, Clovis, USA.
Chamandeep BrarDepartment of Biomedical Education, California Health Sciences University College of Osteopathic Medicine, Clovis, USA.
Sadeepa BulathsinhalaDepartment of Biomedical Education, St. George's University School of Medicine, True Blue, GRD.
Jonathan TerryDepartment of Specialty Medicine, California Health Sciences University College of Osteopathic Medicine, Clovis, USA.
Sudhakar PemminatiDepartment of Biomedical Education, California Health Sciences University College of Osteopathic Medicine, Clovis, USA.
Sudhakar K ShenoyDepartment of Psychiatry, Clarity Clinic, Chicago, USA.
Clarity Water Treatment Systems (Norway) · NOSt. George's University · GDPhiladelphia College of Osteopathic Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mental health disorders are among the top leading causes of disease burden worldwide and many patients have high levels of treatment resistance. Even though medications offer improvement to some patients, antidepressants are only effective in about half of those treated, and schizophrenia is treatment-refractory in about one-third of patients. One way to combat this disparity is to improve medication development and discovery for psychiatric disorders through evidence-based research. Recently, most psychiatric medications approved by the United States Food and Drug Administration (FDA) are for increased tolerability or extended release. Because of the slow, incremental progress, there is a pressing need to explore novel medications with new indications or mechanisms of action to treat the expanding population with mental disorders, especially in those who are fully or partially recalcitrant to first-line medication options. This review aims to present the newest FDA medications with new indications, establish the clinical need for each, and discuss future directions in drug development. We searched and reviewed novel psychiatric medications approved by the FDA from 2018 to 2022. We then analyzed each medication in the United States Clinical Trials Registry and gathered updated results for efficacy and safety information. We also searched PubMed/MEDLINE (Medical Literature Analysis and Retrieval System Online), Scopus, Web of Science, Elsevier, and Google Scholar to understand how these new indications met current clinical needs. Finally, we inquired about related technological implications that will lead the field of psychopharmacology now and in the years to come. We found 12 novel psychiatric medications approved by the FDA from 2018 to 2022, representing a very small percentage of the total FDA approvals during that period. These psychiatric medications with novel mechanisms or improved efficacy and safety  are expected to provide further options for treating mental health disorders; promising results will lead to new patterns of research.

Indexed as

bremelanotidebrexanolonelofexidinepitolisantsolriamfetol

Identifiers

PMID38646400
PMCPMC11028406
OpenAlexW4392985384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.